TP53 and neoplasm: Evidence has suggested that differences in patient characteristics and tumor pathophysiologic characteristics (such as luminal A to luminal B ratio, frequency of TP53 mutations, and tumor‐infiltrating lymphocyte gene signatures) between Asian and nonAsian patients may affect the observed response to treatment in clinical trials.3